Thierry Bilbault

Title: Innovations in Parkinson's Disease Treatment by Thierry Bilbault

Introduction

Thierry Bilbault is a notable inventor based in Cambridge, MA (US), recognized for his contributions to the field of pharmaceuticals, particularly in the treatment of Parkinson's disease. He holds 2 patents that focus on innovative methods and formulations aimed at improving patient outcomes.

Latest Patents

Bilbault's latest patents describe methods of treating Parkinson's disease through the administration of apomorphine to the oral mucosa. These patents detail pharmaceutical unit dosage forms that are films containing a first portion with particles of an acid addition salt of apomorphine and a second portion with a pH neutralizing agent. The films are designed to be flexible and possess a toughness greater than 100 g·mm. The methods outlined can involve administering a therapeutic dose sufficient to achieve an apomorphine plasma concentration of at least 2.64 ng/mL within 45 minutes post-administration. Furthermore, the subject may be categorized based on their uptake of apomorphine as low, medium, or high.

Career Highlights

Bilbault is currently associated with Sunovion Pharmaceuticals Inc., where he continues to innovate in the pharmaceutical sector. His work is pivotal in developing effective treatments for patients suffering from Parkinson's disease, showcasing his commitment to enhancing therapeutic options.

Collaborations

Some of his notable coworkers include Scott David Barnhart and Michael Clinton Koons, who contribute to the collaborative efforts in research and development within the company.

Conclusion

Thierry Bilbault's innovative work in the treatment of Parkinson's disease through novel pharmaceutical formulations highlights his significant impact on the field. His patents represent a step forward in providing effective therapies for patients, demonstrating the importance of continued research and innovation in healthcare.